Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 20/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA3 | P07451 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sezolamide SCHEMBL6086814 | 1.00 | CA2 (1.00) | CA2CA12CA1CA3AR | |
| Sezolamide SCHEMBL9879354 | 1.00 | CA2 (1.00) | CA2CA12CA1CA3AR | |
| Sezolamide SCHEMBL668227 | 0.99 | CA2 (1.00) | CA2 | |
| Sezolamide SCHEMBL6085905 | 0.99 | CA2 (1.00) | CA2 | |
| Sezolamide SCHEMBL8128967 | 0.98 | CA2 (0.98) | CA2 | |
| SCHEMBL9205397 | 0.92 | CA2 (0.85) | CA2CA12CA1CA3AR | |
| SCHEMBL19826857 | 0.89 | CA2 (1.00) | CA2CA12CA1CA3AR | |
| SCHEMBL10513416 | 0.89 | CA2 (1.00) | CA2CA12CA1CA3AR | |
| Hydrochloric Acid SCHEMBL10513807 | 0.85 | CA2 (1.00) | CA2 | |
| SCHEMBL10514131 | 0.84 | CA2 (1.00) | CA2CA12CA1CA3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 557 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-02-19 | — | — | US | claimed |
| EP-4596049-A2 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| EP-4302829-B1 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC (US) | 2025-05-21 | — | — | EP | claimed |
| US-20250090621-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-03-20 | — | — | US | claimed |
| WO-2024254164-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-12-12 | — | — | WO | claimed |
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-10-24 | — | — | US | claimed |
| EP-4419123-A1 | METHODS AND COMPOSITIONS COMPRISING PEPTIDOMIMITICS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS | Stealth BioTherapeutics Inc. (US) | 2024-08-28 | — | — | EP | claimed |
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-02 | — | — | US | claimed |
| US-20240024408-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-01-25 | — | — | US | claimed |
| US-20060177430-A1 | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer | CHAKSHU RESEARCH INC (US) | 2006-08-10 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | TRIER KLAUS (DK) | 2004-01-22 | — | — | US | claimed |
| EP-1112056-B1 | ANTIPERSPIRANT PRODUCT AND METHOD | UNILEVER PLC (GB) | 2003-01-02 | — | — | EP | claimed |
| EP-1112056-A1 | ANTIPERSPIRANT PRODUCT AND METHOD | UNILEVER PLC (GB) | 2001-07-04 | — | — | EP | claimed |
| US-6251376-B1 | NEUTRALIZATION FOR SKINS ELEVATION OF PH OF SWEAT | UNILEVER HOME & PERSONAL CARE USA | 2001-06-26 | — | — | US | claimed |
| WO-2000015185-A1 | ANTIPERSPIRANT PRODUCT AND METHOD | UNILEVER PLC (GB) | 2000-03-23 | — | — | WO | claimed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024408-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | CLN6, PRPH, TSG101 | CA2 1462/4885CA12 2983/4885CA1 3800/4885 |
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | CRYAA, CRYAB, IAPP | CA2 221/4885CA12 1247/4885CA1 2222/4885 |
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | NR2E3, ALDH1A2, PDE6D | CA2 197/4885CA12 2963/4885CA1 2626/4885 |
| US-20250090621-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | PDE6C, PDE6A, PDE6B | CA2 1474/4885CA12 1970/4885CA1 3132/4885 |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | RYR1, ATP2A2, ATP2A1 | CA2 39/4885CA12 876/4885CA1 1185/4885 |
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | CRYAA, CRYAB, PRPH | CA2 1274/4885CA12 3224/4885CA1 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.